Amgen Inc. shares moved 1.14% to $239.52 Wednesday. This proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.18% to 4,219.55 and Dow Jones Industrial Average DJIA falling 0.44% to 34,447.14.
Amgen Inc. closed $37.17 short of its 52-week high ($276.69), which the company achieved on January 28th. The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson JNJ rose 1.35% to $165.59, Roche Holding AG Part. Cert. RHHVF rose 2.69% to $378.82, and Pfizer Inc. PFE rose 2.47% to $39.81.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.